Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 15/20 | 0.84 |
| ▸ | FGFR1 | P11362 | 14/20 | 0.84 |
| ▸ | FGFR3 | P22607 | 14/20 | 0.84 |
| ▸ | ACVR1 | Q04771 | 13/20 | 0.84 |
| ▸ | BMPR1A | P36894 | 5/20 | 0.84 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.84 |
| ▸ | ACVRL1 | P37023 | 5/20 | 0.84 |
| ▸ | HAMP | P81172 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21808466 | 1.00 | FGFR2 (0.84) | FGFR2FGFR1FGFR3ACVR1BMPR1A | |
| SCHEMBL30434129 | 1.00 | FGFR2 (0.84) | FGFR2FGFR1FGFR3ACVR1BMPR1A | |
| SCHEMBL21891903 | 0.91 | FGFR2 (1.00) | FGFR2FGFR1FGFR3ACVR1BMPR1A | |
| SCHEMBL30433839 | 0.91 | FGFR2 (1.00) | FGFR2FGFR1FGFR3ACVR1BMPR1A | |
| SCHEMBL21846661 | 0.91 | FGFR2 (1.00) | FGFR2FGFR1FGFR3ACVR1BMPR1A | |
| SCHEMBL21808525 | 0.87 | FGFR2 (0.82) | FGFR2FGFR1FGFR3ACVR1BMPR1A | |
| SCHEMBL30767261 | 0.87 | ACVR1 (0.73) | FGFR2FGFR1FGFR3ACVR1BMPR1A | |
| SCHEMBL21808325 | 0.85 | ACVR1 (0.83) | FGFR2FGFR1FGFR3ACVR1BMPR1A | |
| SCHEMBL21808324 | 0.83 | FGFR2 (0.60) | FGFR2FGFR1FGFR3ACVR1BMPR1A | |
| SCHEMBL21808358 | 0.80 | FGFR2 (0.83) | FGFR2FGFR1FGFR3ACVR1BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081212-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |